Home > Insider Trading > Filing (0001209191-21-069130)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1653087	Alector Inc.	ALEC	Biological Products, (No Disgnostic Substances) (2836)	822933343

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1713070	Shehnaaz Suliman	C/O Alector, Inc. 131 Oyster Point Blvd, Suite 600 South San Francisco CA 94080	President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-08	19,813	$17.23	122,411	No	4	M	Direct
Common Stock	Acquisiton	2021-12-08	55,187	$10.24	177,598	No	4	M	Direct
Common Stock	Disposition	2021-12-08	36,511	$22.56	141,087	No	4	S	Direct
Common Stock	Disposition	2021-12-08	38,489	$23.01	102,598	No	4	S	Direct
Common Stock	Acquisiton	2021-12-09	75,000	$17.23	177,598	No	4	M	Direct
Common Stock	Disposition	2021-12-09	72,357	$22.80	105,241	No	4	S	Direct
Common Stock	Disposition	2021-12-09	2,643	$23.40	102,598	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-12-08	19,813	$0.00	19,813	$17.23
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-12-08	55,187	$0.00	55,187	$10.24
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-12-09	75,000	$0.00	75,000	$17.23

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
530,187	2029-12-31	No	4	M	Direct
134,026	2030-09-30	No	4	M	Direct
455,187	2029-12-31	No	4	M	Direct

Footnotes

Includes 755 shares acquired on December 1, 2020 and 1,843 shares acquired on June 1, 2021 pursuant to the Issuer's employee stock purchase plan.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.94 to $22.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.94 to $23.10, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $23.35, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.44, inclusive.
One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter.
The shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2020.